<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10566">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00649961</url>
  </required_header>
  <id_info>
    <org_study_id>CR0970 (MIND)</org_study_id>
    <secondary_id>2007-007156-33</secondary_id>
    <nct_id>NCT00649961</nct_id>
  </id_info>
  <brief_title>Melatonin As A Novel Neuroprotectant In Preterm Infants- Dosage Study</brief_title>
  <acronym>MIND</acronym>
  <official_title>Melatonin As A Novel Neuroprotectant In Preterm Infants- Dosage Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>British Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>United Kingdom: National Health Service</authority>
    <authority>United Kingdom: Research Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preterm babies are at risk of brain injury. Melatonin, a naturally occurring hormone, may
      reduce this risk. The unborn baby receives melatonin from the mother but following premature
      delivery there maybe a period of prolonged melatonin deficiency. This deficiency may be
      harmful because studies suggest that melatonin is important in protecting the brain and
      reducing the risk of brain injury after preterm birth. The purpose of this study is to find
      the ideal dose of melatonin to give to preterm babies. We intend to study a total of 24
      babies less than 31 weeks gestation and who are less than 7 days old.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PURPOSE OF THE STUDY AND OBJECTIVES The overall purpose is to investigate whether melatonin,
      on achieving adult maternal peak blood levels in preterm infants, will reduce brain injury
      and white matter disease as defined by specialised magnetic resonance imaging (MRI) at term.
      Before testing this hypothesis in a clinical trial, the dose of melatonin required to
      achieve the desired concentration in preterm infants needs to be determined. This data will
      be used in the clinical double blinded randomised trial for which a separate application
      will be made to the ethics committee.

      The principal research objective in this study is to determine the dose required to achieve
      physiological melatonin blood levels in the preterm infants similar to that of the mother.
      Secondary objective is to define the pharmacokinetic profile of melatonin in preterm
      infants.

      STUDY DESIGN AND METHODOLOGY The proposed clinical trial is a single dose, open label, dose
      escalation pharmacokinetic study in preterm infants less than 31weeks gestation to achieve
      adult peak blood concentrations of melatonin (200-250 pmol/L).

      The trial will be a multi centre study based in the Neonatal Intensive Care Units in UK.

      TREATMENT A single intravenous infusion of melatonin will be given to each infant over 6
      hours once in the first 7 days of life. The starting dose is 0.1 microgram/kg/hr which will
      be increased or decreased incrementally in subsequent groups of infants until the desired
      melatonin concentration is achieved.

      DURATION The duration of treatment will be 6 hours only.

      INVESTIGATIONS Pharmacokinetic assessment will be performed on the blood and urine samples
      will be collected 2 hourly at various timepoints.

      STATISTICAL ANALYSIS Pharmacokinetic assessment will be done using appropriate software.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>To Find the Dose of Melatonin Required to Achieve Physiological Blood Levels in the Preterm Infants Similar to That of the Mother.</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Define the Pharmacokinetic Profile of Melatonin in Preterm Infants.</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Premature Birth</condition>
  <condition>Brain Injury</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin injection</intervention_name>
    <description>A single intravenous infusion of melatonin will be given to each infant over 6 hours so that successive groups will receive increasing doses until the correct dose for age is found.
Based on the pharmacokinetics and clearance of melatonin in adults an approximate dose has been calculated. The starting dose of melatonin will be 0.1 microgram/kg/hr to be given over 6 hours intravenously. The range of expected dose is 0.1-0.5 microgram/kg/hr.</description>
    <other_name>CAS-73314</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infants born less than 31 weeks gestation who are less than 7 days old, after
             parental consent for participation will be included in the study.

        Exclusion Criteria:

          -  Those with major congenital malformation, or cystic periventricular leucomalacia
             (cPVL) or haemorrhagic parenchymal infarcts (HPI) on cranial ultrasonography prior to
             enrolment will be excluded from the study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>23 Weeks</minimum_age>
    <maximum_age>31 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Edwards, FRCPCH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Denis Azzopardi, FRCPCH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nazakat Merchant, MRCPCH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Bolton Hospital</name>
      <address>
        <city>Bolton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.mcrn.org.uk</url>
    <description>Medicines for Children Regulatory Network- adopted study</description>
  </link>
  <link>
    <url>http://www.imperial.nhs.uk/research/researchcentres/neonatal/index.htm</url>
    <description>Neonatal Research at Imperial College - Website for parents</description>
  </link>
  <link>
    <url>http://www.mrc.ac.uk</url>
    <description>UK Medical Research Council- funder for the study</description>
  </link>
  <reference>
    <citation>Jan JE, Wasdell MB, Freeman RD, Bax M. Evidence supporting the use of melatonin in short gestation infants. J Pineal Res. 2007 Jan;42(1):22-7. Review.</citation>
    <PMID>17198535</PMID>
  </reference>
  <reference>
    <citation>Volpe JJ. Cerebral white matter injury of the premature infant-more common than you think. Pediatrics. 2003 Jul;112(1 Pt 1):176-80.</citation>
    <PMID>12837883</PMID>
  </reference>
  <reference>
    <citation>Wood NS, Marlow N, Costeloe K, Gibson AT, Wilkinson AR. Neurologic and developmental disability after extremely preterm birth. EPICure Study Group. N Engl J Med. 2000 Aug 10;343(6):378-84.</citation>
    <PMID>10933736</PMID>
  </reference>
  <verification_date>January 2011</verification_date>
  <lastchanged_date>January 13, 2014</lastchanged_date>
  <firstreceived_date>March 27, 2008</firstreceived_date>
  <firstreceived_results_date>January 13, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Premature Birth</keyword>
  <keyword>Brain injury</keyword>
  <keyword>Neuroprotection</keyword>
  <keyword>Melatonin</keyword>
  <keyword>Pharmacokinetics</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Melatonin</mesh_term>
    <mesh_term>Neuroprotective Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>We conducted an open label dose ranging study between May 2010 and December 2010 in 3 neonatal intensive care units in the UK.</recruitment_details>
      <pre_assignment_details>Infants born less than 31 weeks gestation and less than 7 days old were eligible for the study, although those with: major congenital malformation; or cystic periventricular leucomalacia or haemorrhagic parenchymal infarcts on cranial enrolment were excluded.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Melatonin Open Label Single Arm</title>
          <description>Open label single arm study</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>less than 31 weeks gestation</population>
      <group_list>
        <group group_id="B1">
          <title>Single Arm</title>
          <description>open label dose finding study</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="18"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <description>less than 31 weeks less than 7 days</description>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="26.63" lower_limit="24.71" upper_limit="30.28"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United Kingdom</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="18"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>To Find the Dose of Melatonin Required to Achieve Physiological Blood Levels in the Preterm Infants Similar to That of the Mother.</title>
        <time_frame>6 months</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Single Arm</title>
            <description>open label dose finding study</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>To Find the Dose of Melatonin Required to Achieve Physiological Blood Levels in the Preterm Infants Similar to That of the Mother.</title>
            <units>pg/ml</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="203.3" lower_limit="160" upper_limit="220"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Define the Pharmacokinetic Profile of Melatonin in Preterm Infants.</title>
        <time_frame>6 months</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Single Arm</title>
          <description>open label dose finding study</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Nazakat Merchant</name_or_title>
      <organization>Imperial College London</organization>
      <phone>00447825881907</phone>
      <email>nazakat.merchant@kcl.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
